Abstract
Background Concomitant left atrial appendage exclusion (LAAE) during cardiac surgery is an effective method of reducing stroke risk in patients with atrial fibrillation. Previous studies have documented racial disparities in the performance of multiple cardiac procedures. We sought to evaluate if there were any disparities in the utilization and outcomes of concomitant LAAE.
Methods We used the 2016-2020 National Inpatient Sample database to identify hospitalizations for cardiac surgery in patients with atrial fibrillation with concomitant LAAE. We utilized the weighted data to compare the in-hospital mortality and complications such as stroke, bleeding, infection, heart failure and pericardial complications among different race/ethnic groups.
Results From 2016 to 2020, 432,244 hospitalizations were for cardiac surgery, of which 91,395 (21%) included concomitant LAAE. Of these, 77,440 (84.7%) were in White patients, 4,179 (4.6%) were in Black patients, 4,834 (5.3%) were in Hispanic patients, and 4,939 (5.4%) were in other races. Black and Hispanic patients had lower odds of undergoing concomitant LAAE during cardiac surgery compared to white patients (adjusted odds ratio (aOR) 0.85, 95% confidence interval (CI) 0.79-0.93 and aOR 0.85, 95% CI 0.79-0.93, respectively). There were no significant differences between Black and Hispanic patients in in-hospital mortality or procedural complications except for higher bleeding complications in Hispanic patients (aOR 2.38, 95% CI 1.27-2.86) compared to White patients. Through the study period, the proportion of patients receiving concomitant LAAE increased in all race/ethnic groups.
Conclusion Concomitant LAAE during cardiac surgery is underutilized in Black and Hispanic patients compared to White patients, despite mostly similar clinical outcomes. Further comparative longitudinal studies are warranted to confirm these findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no IRB approval was required for this study as it only unidentified hospitalizations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used for this study is available through HEALTHCARE COST & UTILIZATION PROJECT.
https://hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comorbidity_icd10.jsp.
